Does the media refer more to XERS or LEGN?

In the previous week, Legend Biotech had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Legend Biotech and 6 mentions for Xeris Biopharma. Legend Biotech's average media sentiment score of 1.04 beat Xeris Biopharma's score of 0.19 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XERS or AMRX?

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Xeris Biopharma and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.81 beat Xeris Biopharma's score of 0.19 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XERS or TVTX?

In the previous week, Travere Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Travere Therapeutics and 6 mentions for Xeris Biopharma. Travere Therapeutics' average media sentiment score of 1.35 beat Xeris Biopharma's score of 0.19 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XERS or DNTH?

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Dianthus Therapeutics and 6 mentions for Xeris Biopharma. Dianthus Therapeutics' average media sentiment score of 1.08 beat Xeris Biopharma's score of 0.19 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dianthus Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to XERS or ORKA?

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Oruka Therapeutics and 6 mentions for Xeris Biopharma. Oruka Therapeutics' average media sentiment score of 0.85 beat Xeris Biopharma's score of 0.19 indicating that Oruka Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oruka Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Xeris Biopharma (XERS) Competitors

$8.16 -0.18 (-2.16%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$8.17 +0.01 (+0.16%)

As of 04:58 AM Eastern

Compare

XERS vs. LEGN, AMRX, TVTX, DNTH, and ORKA

Should you buy Xeris Biopharma stock or one of its competitors? MarketBeat compares Xeris Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Xeris Biopharma include Legend Biotech (LEGN), Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), Dianthus Therapeutics (DNTH), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

How does Xeris Biopharma compare to Legend Biotech?

Xeris Biopharma (NASDAQ:XERS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Legend Biotech had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Legend Biotech and 6 mentions for Xeris Biopharma. Legend Biotech's average media sentiment score of 1.04 beat Xeris Biopharma's score of 0.19 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a net margin of 3.81% compared to Legend Biotech's net margin of -21.98%. Xeris Biopharma's return on equity of 735.00% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Legend Biotech	-21.98%	-24.92%	-14.87%

Xeris Biopharma currently has a consensus price target of $10.80, suggesting a potential upside of 32.35%. Legend Biotech has a consensus price target of $57.00, suggesting a potential upside of 121.36%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Legend Biotech is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.60

Xeris Biopharma has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.83	$550K	$0.06	136.00
Legend Biotech	$1.03B	4.65	-$296.80M	-$0.68	N/A

Summary

Xeris Biopharma beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Xeris Biopharma (NASDAQ:XERS) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Xeris Biopharma had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Xeris Biopharma and 4 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.81 beat Xeris Biopharma's score of 0.19 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma presently has a consensus target price of $10.80, suggesting a potential upside of 32.35%. Amneal Pharmaceuticals has a consensus target price of $15.80, suggesting a potential downside of 8.03%. Given Xeris Biopharma's higher possible upside, analysts plainly believe Xeris Biopharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amneal Pharmaceuticals has a net margin of 4.01% compared to Xeris Biopharma's net margin of 3.81%. Xeris Biopharma's return on equity of 735.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Xeris Biopharma has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Xeris Biopharma. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.83	$550K	$0.06	136.00
Amneal Pharmaceuticals	$3.02B	1.82	$72.06M	$0.38	45.21

Summary

Amneal Pharmaceuticals beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Travere Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

Xeris Biopharma has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Xeris Biopharma has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.83	$550K	$0.06	136.00
Travere Therapeutics	$490.73M	10.67	-$25.55M	-$0.23	N/A

In the previous week, Travere Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 7 mentions for Travere Therapeutics and 6 mentions for Xeris Biopharma. Travere Therapeutics' average media sentiment score of 1.35 beat Xeris Biopharma's score of 0.19 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 32.35%. Travere Therapeutics has a consensus target price of $52.08, indicating a potential downside of 7.47%. Given Xeris Biopharma's higher possible upside, equities analysts plainly believe Xeris Biopharma is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

42.8% of Xeris Biopharma shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to Travere Therapeutics' net margin of -4.00%. Xeris Biopharma's return on equity of 735.00% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Summary

Xeris Biopharma and Travere Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Xeris Biopharma compare to Dianthus Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Dianthus Therapeutics (NASDAQ:DNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Xeris Biopharma currently has a consensus target price of $10.80, indicating a potential upside of 32.35%. Dianthus Therapeutics has a consensus target price of $117.82, indicating a potential upside of 19.44%. Given Xeris Biopharma's higher possible upside, equities analysts clearly believe Xeris Biopharma is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Dianthus Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Dianthus Therapeutics and 6 mentions for Xeris Biopharma. Dianthus Therapeutics' average media sentiment score of 1.08 beat Xeris Biopharma's score of 0.19 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dianthus Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to Dianthus Therapeutics' net margin of -12,998.50%. Xeris Biopharma's return on equity of 735.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Dianthus Therapeutics	-12,998.50%	-27.30%	-25.91%

Xeris Biopharma has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.83	$550K	$0.06	136.00
Dianthus Therapeutics	$2.04M	2,643.46	-$162.34M	-$4.13	N/A

42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 4.4% of Xeris Biopharma shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Xeris Biopharma beats Dianthus Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Xeris Biopharma compare to Oruka Therapeutics?

Xeris Biopharma (NASDAQ:XERS) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Xeris Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market.

Xeris Biopharma has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.83	$550K	$0.06	136.00
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

In the previous week, Oruka Therapeutics had 3 more articles in the media than Xeris Biopharma. MarketBeat recorded 9 mentions for Oruka Therapeutics and 6 mentions for Xeris Biopharma. Oruka Therapeutics' average media sentiment score of 0.85 beat Xeris Biopharma's score of 0.19 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oruka Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 32.35%. Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 58.82%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Xeris Biopharma has a net margin of 3.81% compared to Oruka Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Oruka Therapeutics	N/A	-26.16%	-25.00%

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Xeris Biopharma beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XERS vs. The Competition

Export

Metric	Xeris Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.44B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	136.00	19.17	27.11	24.26
Price / Sales	4.83	838.79	589.14	117.88
Price / Cash	83.26	56.80	29.22	49.36
Price / Book	102.00	4.22	10.75	6.29
Net Income	$550K	$64.26M	$3.58B	$330.66M
7 Day Performance	-8.72%	-3.58%	-2.10%	-1.35%
1 Month Performance	20.18%	2.12%	3.29%	-0.64%
1 Year Performance	50.00%	20.35%	26.32%	19.08%

Xeris Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XERS Xeris Biopharma	3.4056 of 5 stars	$8.16 -2.2%	$10.80 +32.4%	+59.7%	$1.44B	$291.85M	136.00	290
LEGN Legend Biotech	3.5135 of 5 stars	$28.04 -6.3%	$60.23 +114.8%	-33.9%	$5.56B	$1.03B	N/A	2,965	News Coverage Positive News Analyst Forecast
AMRX Amneal Pharmaceuticals	2.1145 of 5 stars	$16.92 -1.3%	$15.80 -6.6%	+106.2%	$5.47B	$3.02B	20.92	8,500	News Coverage Analyst Upgrade
TVTX Travere Therapeutics	2.0277 of 5 stars	$57.48 +1.0%	$52.08 -9.4%	+241.8%	$5.29B	$490.73M	N/A	460	Positive News
DNTH Dianthus Therapeutics	2.8348 of 5 stars	$93.34 -1.1%	$117.82 +26.2%	+391.7%	$5.16B	$2.04M	N/A	80	News Coverage Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XERS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Xeris Biopharma (XERS) Competitors

XERS vs. LEGN, AMRX, TVTX, DNTH, and ORKA

How does Xeris Biopharma compare to Legend Biotech?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Summary

How does Xeris Biopharma compare to Dianthus Therapeutics?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Xeris Biopharma (XERS) Competitors

XERS vs. LEGN, AMRX, TVTX, DNTH, and ORKA

How does Xeris Biopharma compare to Legend Biotech?

Which has more volatility and risk, XERS or LEGN?

Do insiders & institutionals believe in XERS or LEGN?

Does the media refer more to XERS or LEGN?

Is XERS or LEGN more profitable?

Do analysts rate XERS or LEGN?

Which has better earnings & valuation, XERS or LEGN?

Summary

How does Xeris Biopharma compare to Amneal Pharmaceuticals?

Do insiders and institutionals have more ownership in XERS or AMRX?

Does the media refer more to XERS or AMRX?

Do analysts rate XERS or AMRX?

Is XERS or AMRX more profitable?

Which has more volatility & risk, XERS or AMRX?

Which has higher earnings & valuation, XERS or AMRX?

Summary

How does Xeris Biopharma compare to Travere Therapeutics?

Which has more volatility and risk, XERS or TVTX?

Which has stronger earnings & valuation, XERS or TVTX?

Does the media prefer XERS or TVTX?

Do analysts recommend XERS or TVTX?

Do institutionals and insiders believe in XERS or TVTX?

Is XERS or TVTX more profitable?

Summary

How does Xeris Biopharma compare to Dianthus Therapeutics?

Do analysts prefer XERS or DNTH?

Does the media refer more to XERS or DNTH?

Which has more volatility and risk, XERS or DNTH?

Is XERS or DNTH more profitable?

Which has better valuation & earnings, XERS or DNTH?

Do institutionals & insiders have more ownership in XERS or DNTH?

Summary

How does Xeris Biopharma compare to Oruka Therapeutics?

Which has more risk & volatility, XERS or ORKA?

Which has higher valuation & earnings, XERS or ORKA?

Does the media refer more to XERS or ORKA?

Do analysts recommend XERS or ORKA?

Is XERS or ORKA more profitable?

Do institutionals & insiders have more ownership in XERS or ORKA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XERS vs. The Competition

Xeris Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools